SG11201500480TA - Article of manufacture comprising aflibercept or ziv-aflibercept - Google Patents

Article of manufacture comprising aflibercept or ziv-aflibercept

Info

Publication number
SG11201500480TA
SG11201500480TA SG11201500480TA SG11201500480TA SG11201500480TA SG 11201500480T A SG11201500480T A SG 11201500480TA SG 11201500480T A SG11201500480T A SG 11201500480TA SG 11201500480T A SG11201500480T A SG 11201500480TA SG 11201500480T A SG11201500480T A SG 11201500480TA
Authority
SG
Singapore
Prior art keywords
aflibercept
ziv
article
manufacture
Prior art date
Application number
SG11201500480TA
Inventor
Sylvie Assadourian
Rémi Castan
Emmanuelle Magherini
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of SG11201500480TA publication Critical patent/SG11201500480TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D85/00—Containers, packaging elements or packages, specially adapted for particular articles or materials
    • B65D85/70—Containers, packaging elements or packages, specially adapted for particular articles or materials for materials not otherwise provided for
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mechanical Engineering (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Wrappers (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201500480TA 2012-08-02 2013-08-02 Article of manufacture comprising aflibercept or ziv-aflibercept SG11201500480TA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261678983P 2012-08-02 2012-08-02
US201261679490P 2012-08-03 2012-08-03
PCT/EP2013/066299 WO2014020160A1 (en) 2012-08-02 2013-08-02 Article of manufacture comprising aflibercept or ziv-aflibercept

Publications (1)

Publication Number Publication Date
SG11201500480TA true SG11201500480TA (en) 2015-02-27

Family

ID=48917540

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201500480TA SG11201500480TA (en) 2012-08-02 2013-08-02 Article of manufacture comprising aflibercept or ziv-aflibercept

Country Status (17)

Country Link
US (2) US20150216795A1 (en)
EP (1) EP2879694A1 (en)
JP (1) JP2015526430A (en)
KR (1) KR20150038297A (en)
CN (1) CN104853763A (en)
AR (1) AR091967A1 (en)
AU (1) AU2013298521A1 (en)
CA (1) CA2888281A1 (en)
EA (1) EA201590305A1 (en)
HK (1) HK1206628A1 (en)
IL (1) IL236931A0 (en)
MX (1) MX2015001550A (en)
SG (1) SG11201500480TA (en)
TW (1) TW201408316A (en)
UY (1) UY34962A (en)
WO (1) WO2014020160A1 (en)
ZA (1) ZA201500485B (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3283B1 (en) 2011-04-26 2018-09-16 Sanofi Sa Composition comprising aflibercept, folinic acid, 5-fluorouracil (5-fu) and irinocetan (folfiri)
AR095196A1 (en) 2013-03-15 2015-09-30 Regeneron Pharma SERUM FREE CELL CULTIVATION MEDIA
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
TR201909951T4 (en) 2014-07-18 2019-07-22 Sanofi Sa A method for predicting the outcome of aflibercept treatment of a patient suspected of having cancer.
WO2016202785A1 (en) 2015-06-17 2016-12-22 Novozymes A/S Container
TW202340452A (en) 2015-08-04 2023-10-16 美商再生元醫藥公司 Taurine supplemented cell culture medium and methods of use
KR101936049B1 (en) 2015-10-15 2019-01-08 (주)알테오젠 Method for manufacturing fusion proteins with IgG Fc domain
KR20180104635A (en) 2015-12-30 2018-09-21 코디악 사이언시스 인코포레이티드 Antibodies and conjugates thereof
KR102652347B1 (en) * 2016-01-25 2024-03-27 사노피 Method for predicting outcome of treatment with aflibercept in patients suspected of having cancer by measurement of plasma biomarker levels
TW201934570A (en) * 2017-07-06 2019-09-01 美商雷傑納榮製藥公司 Cell culture process for making a glycoprotein
CN109929038B (en) * 2017-12-15 2020-10-09 山东博安生物技术有限公司 Purification method of VEGF (vascular endothelial growth factor) capture agent fusion protein
CN109929027B (en) * 2017-12-15 2020-10-09 山东博安生物技术有限公司 Method for purifying recombinant fusion protein by linear elution step
US20200115443A1 (en) * 2018-10-12 2020-04-16 Trican Biotechnology Co., Ltd Bi-functional fusion proteins and uses thereof
JP2022523063A (en) * 2019-01-30 2022-04-21 アムジエン・インコーポレーテツド Aflibercept attributes and their characterization and modification methods
CN114786731A (en) 2019-10-10 2022-07-22 科达制药股份有限公司 Methods of treating ocular disorders
CN114206924A (en) 2019-12-06 2022-03-18 瑞泽恩制药公司 anti-VEGF protein composition and preparation method thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1861116T3 (en) * 2005-03-25 2015-11-09 Regeneron Pharma VEGF antagonist formulations
JO3283B1 (en) * 2011-04-26 2018-09-16 Sanofi Sa Composition comprising aflibercept, folinic acid, 5-fluorouracil (5-fu) and irinocetan (folfiri)

Also Published As

Publication number Publication date
TW201408316A (en) 2014-03-01
CA2888281A1 (en) 2014-02-06
HK1206628A1 (en) 2016-01-15
MX2015001550A (en) 2015-05-11
AR091967A1 (en) 2015-03-11
UY34962A (en) 2014-02-28
KR20150038297A (en) 2015-04-08
EA201590305A1 (en) 2015-06-30
US20150216795A1 (en) 2015-08-06
EP2879694A1 (en) 2015-06-10
WO2014020160A1 (en) 2014-02-06
IL236931A0 (en) 2015-03-31
AU2013298521A1 (en) 2015-02-26
JP2015526430A (en) 2015-09-10
CN104853763A (en) 2015-08-19
US20180078496A1 (en) 2018-03-22
ZA201500485B (en) 2017-07-26

Similar Documents

Publication Publication Date Title
HK1206628A1 (en) Article of manufacture comprising aflibercept or ziv-aflibercept ziv-
HK1214096A1 (en) Article of footwear
HK1198877A1 (en) Smoking article
GB201209415D0 (en) Manufacture of metal articles
AU347566S (en) Article of jewellery
EP2932496A4 (en) Glass and methods of making glass articles
GB201418086D0 (en) Methods of transfering discrete articles
SG11201500187WA (en) Methods of manufacturing cartilage products
HK1202031A1 (en) Smoking articles
EP2863856A4 (en) Wearing article
EP2900192A4 (en) Wearing article
SG11201405941QA (en) Article and method of making the same
EP2926985A4 (en) Article having glass-like design
HK1212659A1 (en) Chemical-packed article
EP2883522A4 (en) Underwear-type worn article
HK1206216A1 (en) Footwear article
GB201217680D0 (en) Smoking article
PL2712510T3 (en) Smoking article
GB2501671A8 (en) Smoking article
GB201206445D0 (en) Article selection
TWM433124U (en) Structure of decoration article
HK1209991A1 (en) Ornamental articles
GB201223502D0 (en) Smoking article
AU346353S (en) Smoker article
GB201312268D0 (en) Articles of manufacture